Spironolactone and Prevention of Calcineurin Inhibitor Toxicity in Kidney Transplant Recipients

• Status: Suspended
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The main objective of this study is to assess the effect of spironolactone on interstitial fibrosis in kidney transplant recipients receiving calcineurin inhibitors

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez
• Treatments: Calcineurin Inhibitors; Spironolactone

Criteria

Inclusion Criteria:

• Kidney Failure

• Age > 18

• Kidney transplant recipients

Exclusion Criteria:

• Patients taking angiotensin receptor blockers or inhibitors of the angiotensin reconverting enzyme

• Kidney transplant performed more than one month from enrollment in the study

• Hyperkalemia (K> 5.5 meqL)